Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21095146 | 1.00 | L3MBTL1 (0.66) | L3MBTL1CYP2D6HTR2AABCB1ADRB2 | |
| SCHEMBL21094969 | 1.00 | L3MBTL1 (0.66) | L3MBTL1CYP2D6HTR2AABCB1ADRB2 | |
| SCHEMBL21095154 | 0.94 | CYP2D6 (0.62) | L3MBTL1CYP2D6HTR2AABCB1ADRB2 | |
| SCHEMBL21095151 | 0.94 | CYP2D6 (0.62) | L3MBTL1CYP2D6HTR2AABCB1ADRB2 | |
| SCHEMBL21095155 | 0.94 | CYP2D6 (0.62) | L3MBTL1CYP2D6HTR2AABCB1ADRB2 | |
| SCHEMBL21095017 | 0.91 | CYP2D6 (0.67) | CYP2D6HTR2AABCB1SMN1; SMN2HTR1A | |
| SCHEMBL21095148 | 0.91 | CYP2D6 (0.67) | CYP2D6HTR2AABCB1SMN1; SMN2HTR1A | |
| SCHEMBL21095150 | 0.91 | CYP2D6 (0.67) | CYP2D6HTR2AABCB1SMN1; SMN2HTR1A | |
| SCHEMBL21094968 | 0.90 | CYP2D6 (0.66) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| SCHEMBL21094966 | 0.90 | CYP2D6 (0.66) | CYP2D6HTR2AABCB1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA (UG) (haftungsbeschränkt) (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | L3MBTL1 4529/4885CYP2D6 9/4885HTR2A 1/4885 |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | L3MBTL1 4523/4885CYP2D6 7/4885HTR2A 1705/4885 |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP11B2, CYP2D6 | L3MBTL1 4471/4885CYP2D6 3/4885HTR2A 2171/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | L3MBTL1 4391/4885CYP2D6 17/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.